Successful management of an extreme example of neonatal hyperprostaglandin-E syndrome (Bartter's syndrome) with the new cyclooxygenase-2 inhibitor rofecoxib

Pediatric Critical Care Medicine

Volumn 4, Issue 2, 2003, Pages 249-251

  Haas, Nikolaus A ^a   Nossal, Robert ^a   Schneider, Christoph H ^a   Lewin, Martin A G ^a   Ocker, Volker ^a   Holder, Martin ^a   Uhlemann, Frank ^a  

^a Olgahospital Stuttgart ^*  (Germany)

Author keywords

Cyclooxygenase 2 inhibitor; Hyperprostaglandin E syndrome; Hypokalemia; Indomethacin; Neonatal Bartter's syndrome

Indexed keywords

LACTONE; PROSTAGLANDIN SYNTHASE INHIBITOR; ROFECOXIB; SULFONE;

ARTICLE; BARTTER SYNDROME; CASE REPORT; HUMAN; NEWBORN; PATHOPHYSIOLOGY;

BARTTER SYNDROME; CYCLOOXYGENASE INHIBITORS; HUMANS; INFANT, NEWBORN; LACTONES; SULFONES;

EID: 0038148126     PISSN: 15297535     EISSN: 19473893     Source Type: Journal    
DOI: 10.1097/01.PCC.0000059422.26706.64     Document Type: Article

References (29)

1. Madrigal G, Saborio P, Mora F, et al: Bartter syndrome in Costa Rica: A description of 20 cases. Pediatr Nephrol 1997; 11:296-301
2. Köckerling A, Konrad M, Seyberth HW: Hereditäre Tubulopathien mit Diuretikaähnlichem Salzverlust. Dtsch Ärzteblatt 1998; 95:A1841-A1846
3. Jeck N, Konrad M, Hess M, et al: The diuretic- and Bartter-like salt-losing tubulopathies. Nephrol Dial Transplant 2000; 15
4. Bockenhauer D: Ion channel in disease. Curr Opin Pediatr 2001; 13:142-149
5. Simon DB, Karet FE, Rodriguez-Soriano J, et al: Genetic heterogeneity of Bartter's syndrome revealed by mutations in the K- channel, ROMK. Nat Genet 1996; 14:152-156
6. Károlyi L, Ziegler A, Pollak M, et al: Gitelman's syndrome is genetically distinct from other forms of Bartter's syndrome. Pediatr Nephrol 1996; 10:551-554
7. Simon DB, Lifton RP: The molecular basis of inherited hypokalemic alkalosis: Bartter's and Gitelman's syndromes. Am J Physiol 1996; 271:F961-F966
8. Konrad M, Vollmer M, Lemmink H, et al: Mutations in the chloride channel gene CLCNKB as a cause of classic Bartter syndrome. J Am Soc Nephrol 2000; 11:1449-1459
9. Bettinelli A, Ciarmatori S, Cesareo L, et al: Phenotypic variability in Bartter syndrome type I. Pediatr Nephrol 2000; 14:940-945
10. Proesmans W: Bartter syndrome and its neonatal variant. Eur J Pediatr 1997; 156:669-679
11. Rodriguez-Soriano J: Bartter and related syndromes: The puzzle is almost solved. Pediatr Nephrol 1998:315-327
12. Williams MP, Jones CL, Johnstone LM, et al: An extreme example of the neonatal form of Bartter's syndrome. Pediatr Nephrol 1996; 10:496-497
13. Seyberth HW, Leonhardt A, Soergel M: Das Hyperprostaglandin-E2-Syndrom. Monatsschr Kinderheilk 1994; 142:392-395
14. Konrad M, Leonhardt A, Hensen P, et al: Prenatal and postnatal management of hyperprostaglandin E syndrome after genetic diagnosis from amniocytes. Pediatrics 1999; 103: 678-683
15. Komhoff M, Jeck ND, Seyberth WW, et al: Cyclooxygenase-2 expression is associated with the renal macula densa of patients with Bartter-like syndrome. Kidney Int 2000; 58: 2420-2424
16. Craig JC, Falk MC: Indomethacin for renal impairment in neonatal Bartter's syndrome. Lancet 1996; 347:550
17. Mackie FE, Hodson EM, Roy LP, et al: Neonatal Bartter's syndrome: Use of indomethacin in the newborn period and prevention of growth failure. Pediatr Nephrol 1996; 10:756-758
18. Proesmans W, Massa G, Vanderschueren- Lodeweyckx M: Growth from birth to adulthood in a patient with the neonatal form of Bartter syndrome. Pediatr Nephrol 1988; 2:205-209
19. Mourani CC, Sanjad SA, Akatcherian CY: Bartter syndrome in a neonate: Early treatment with indomethacin. Pediatr Nephrol 2000; 14:143-145
20. Nakagawa Y, Toya K, Natsume H, et al: Longterm follow-up of a girl with the neonatal form of Bartter's syndrome. Endocr J 1997; 44:275-281
21. Proesmans W, Devlieger H, Van Assche A, et al: Bartter syndrome in two siblings: Antenatal and neonatal observations. Int J. Pediatr Nephrol 1985; 6:63-70
22. O'Sullivan E, Monga M, Graves W: Bartter's syndrome in pregnancy: A case report and review. Am J Perinatol 1997; 14:55-57
23. Reinalter SC, Grone HJ, Konrad M, et al: Evaluation of long-term treatment with indomethacin in hereditary hypokalemic salt-losing tubulopathies. J Pediatr 2001; 139:398-406
24. Marlow N, Chiswick ML. Neonatal Bartter's syndrome, indomethacin and necrotizing enterocolitis. Acta Paediatr Scand 1982; 71: 1031-1032
25. Schmidt H, Geisslinger G: Selektive Cyclooxygenase- 2-Hemmer Pharmakologie und Kenntnisstand nach Markteinfuhrung. Schmerz 2001; 15:207-219
26. Kleta R, Basoglu C, Kuwertz-Brocking E: New treatment options for Bartter's syndrome. N Engl J Med 2000; 323:661-662
27. Jeck N, Reinalter SC, Henne T, et al: Hypokalemic salt-losing tubulopathy with chronic renal failure and sensorineural deafness. Pediatrics 2001; 108:E5
28. Birkenhager R, Otto E, Schurmann MJ, et al: Mutation of BSND causes Bartter syndrome with sensorineural deafness and kidney failure. Nat Genet 2001; 29:310-4
29. Scott LJ, Lamb HM. Rofecoxib. Drugs 1999; 58:499-505